Shots:
- AstraZeneca has reported P-III (NATRON) trial data assessing Fasenra (30mg, SC, Q4W) vs PBO, both in addition to background HES therapy in 133 HES pts for 24wks.
- Trial met its 1EP of delayed time to first HES worsening or flare & reduced the risk of HES worsening/flare by 65%
- Trial met all 2EPs, showing fewer flares or withdrawals (22.4% vs 45.5%), a 66% reduction in annualized rate of HES flares (0.41 vs 1.23/year), delayed time to first hematologic relapse, & sustained PROMIS Fatigue improvement from Wk. 4 to 24; data to be presented at ASH & ACAAI’25
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca Reports the EC’s Approval of Koselugo (Selumetinib) for Treating Neurofibromatosis Type 1
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
